Contact this trialFirst, we need to learn more about you.
NMDA Receptor Antagonist
SLS-002 for Major Depressive Disorder
Recruiting0 awardsPhase 2
Springfield, Illinois
This trial is testing a nasal spray with ketamine for people with severe depression who are at high risk of suicide. The spray aims to quickly improve mood by balancing brain chemicals. Esketamine was approved to treat treatment-resistant depression.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service